

Supplemental material is neither peer-reviewed nor thoroughly edited by CJASN. The authors alone are responsible for the accuracy and presentation of the material.

SUPPLEMENTAL MATERIAL

REGULATORY CONSIDERATIONS FOR HEMODIAFILTRATION IN THE UNITED STATES

Richard A. Ward, Ph.D., Jörg Vienken, Ph.D., Douglas M. Silverstein, M.D., Stephen Ash, M.D. and Bernard Canaud, M.D., Ph.D., on behalf of the Kidney Health Initiative HDF Workgroup

Appendix 1: Members of the Kidney Health Initiative “Regulatory Policies and Positions Affecting Device Approval in the US: Tools to Assess the Process and Foster Device Development for Patients with Kidney Disease” Workgroup’s Hemodiafiltration Subgroup and their affiliations

Members of the Kidney Health Initiative “Regulatory Policies and Positions Affecting Device Approval in the US: Tools to Assess the Process and Foster Device Development for Patients with Kidney Disease” Workgroup’s Hemodiafiltration Subgroup and their affiliations

Stephen R. Ash, MD, FACP
HemoCleanse Technologies, LLC,
Indiana University Health Arnett, and
Ash Access Technology, Inc.
(Workgroup Co-chair)

Bernard Canaud, MD, PhD
Fresenius Medical Care – Germany
Montpellier University, France

Greg Collins, PhD
Nephros, Inc.

William Fissell, MD
Vanderbilt University

Gema Gonzalez, MS
Center for Devices and Radiological
Health (CDRH), FDA

Shani Haugen, PhD
Center for Drug Evaluation and
Research (CDER), FDA

Robert Kossmann, MD, FACP, FASN
Fresenius Medical Care - North
America

Carolyn Y. Neuland, PhD
Center for Devices and Radiological
Health (CDRH), FDA
(KHI Board of Directors Liaison)

Douglas M. Silverstein, MD
Center for Devices and Radiological
Health (CDRH), FDA
(Workgroup Co-chair)

Todd Snell
NxStage Medical, Inc.

Jim Summerton
Nephros, Inc.

Jorg Vienken, PhD
Usingen, Germany

Richard A. Ward, PhD
New Zealand

Shen Xiao, MD
Center for Devices and Radiological
Health (CDRH), FDA